Grisnilimab

Tax included
Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA.
MedChemExpress 
HY-P99650

Data sheet

Size
Multiple sizes
Reactivity
Others
Application
Cancer-programmed cell death
CAS
2367001-70-3